Laura Abriola, M.S., joined YCMD in 2009. Her expertise includes cell, organism, and biochemical-based assay development and optimization as well as high throughput screening activities. Before joining Yale, Laura worked in the Pharmaceutical and Biotechnology industries including Cara Therapeutics, Bayer, Novartis, and Johnson and Johnson for 21 years. She developed and performed cell-based and biochemical assays for high throughput screening, lead optimization, and clinical biomarker discovery for a series of biomedical applications including programs in oncology, immunology, and neurology. Since being at YCMD, Laura has developed expertise in whole organism, siRNA, and high content screening. She has worked on several cell-based, biochemical and organism screens resulting in validated hits. Laura specializes in optimization of particularly difficult assays and over the years has learned many approaches to developing robust assays suitable for screening. Laura has a M.S in Biochemistry and Microbiology from Rutgers, the State University of New Jersey and a B.S. in Biology from the University of Connecticut.